BrainsWay Ltd. (BWAY)
| Market Cap | 488.36M +68.2% |
| Revenue (ttm) | 60.70M +31.7% |
| Net Income | 9.44M +76.7% |
| EPS | 0.23 +109.9% |
| Shares Out | 40.13M |
| PE Ratio | 51.73 |
| Forward PE | 33.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,179 |
| Open | 12.29 |
| Previous Close | 12.50 |
| Day's Range | 11.93 - 12.34 |
| 52-Week Range | 7.14 - 17.40 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 19.27 (+57.56%) |
| Est. Earnings | Nov 10, 2026 |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $19.27, which is an increase of 57.56% from the latest price.
News
BrainsWay Reports Positive Pilot Study Results For Deep TMS In Depression & Early Alzheimer's
(RTTNews) - BrainsWay Ltd. (BWAY) on Tuesday reported results from a peer-reviewed pilot study evaluating its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in patients with major depres...
Brainsway publishes results from pilot study
BrainsWay (BWAY) announced the publication of results from a pilot study evaluating the company’s proprietary Deep Transcranial Magnetic Stimulation technology in patients with co-occurring Major Depr...
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Brainsway price target raised to $19 from $17 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $19 from $17 and keeps a Buy rating on the shares. The company’s Q2 financial results…
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway reports Q2 EPS 7c, consensus 7c
Reports Q2 revenue $12.77M, consensus $16.54M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a re...
Brainsway raises FY26 revenue view to $68M-$70M from $66M-$68M
Consensus $67.65M. Narrows FY26 adjusted EBITDA view to $13M-$14M from $12M-$14M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in opera...
Brainsway price target raised to $18.80 from $18 at Ladenburg
Ladenburg raised the firm’s price target on Brainsway (BWAY) to $18.80 from $18 and keeps a Buy rating on the shares post the Q2 report. The firm says the company’s…
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its ac...
BrainsWay Earnings Call Transcript: Q2 2026
Q2 2026 saw 35% revenue growth, margin expansion, and strong recurring revenue visibility, driven by robust Deep TMS system demand and SWIFT protocol adoption. Full-year guidance was raised, supported by a growing backlog, strategic investments, and a debt-free balance sheet.
BrainsWay Earnings release: Q2 2026
BrainsWay released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
BrainsWay Ltd (BWAY) Shares Surge 11.0% -- What GF Score of 58 Tells Investors
BrainsWay Ltd (BWAY) Shares Surge 11.0% -- What GF Score of 58 Tells Investors
BrainsWay Releases Q2 2026 Financial Results
BrainsWay Ltd. The post BrainsWay Releases Q2 2026 Financial Results first appeared on Alphastreet .
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
Earnings To Watch: BrainsWay Ltd (BWAY) Q2 2026 -- GF Value Sees 35% Downside
Earnings To Watch: BrainsWay Ltd (BWAY) Q2 2026 -- GF Value Sees 35% Downside
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Brainsway and Lululemon athletica have been highlighted as Zacks Bull and Bear of the Day
BWAY earns Bull of the Day on expanding Deep TMS adoption, while LULU lands Bear of the Day as slowing growth and falling estimates weigh on outlook.
Bull of the Day: Brainsway (BWAY)
Brainsway shares have rallied more than 60% this year, with more bullish tailwinds at its back.
Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.
BrainsWay Ltd (BWAY) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 65/100
BrainsWay Ltd (BWAY) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 65/100
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to active...
Brainsway initiated with a Buy at BTIG
BTIG initiated coverage of Brainsway (BWAY) with a Buy rating and $18 price target The company has demonstrated the ability to scale a transcranial magnetic stimulation business into sustainable profi...
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports Brai...